Deborah Ann Miller Sells 700 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 700 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $109.84, for a total transaction of $76,888.00. Following the transaction, the insider directly owned 59,634 shares in the company, valued at approximately $6,550,198.56. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Deborah Ann Miller also recently made the following trade(s):

• On Thursday, January 22nd, Deborah Ann Miller sold 14,300 shares of Nuvalent stock. The shares were sold at an average price of $110.16, for a total transaction of $1,575,288.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The shares were sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Trading Down 5.0%

NUVL traded down $5.55 during trading on Friday, reaching $106.44. 448,397 shares of the company’s stock were exchanged, compared to its average volume of 619,348. Nuvalent, Inc. has a one year low of $55.53 and a one year high of $113.01. The firm has a fifty day moving average price of $104.92 and a two-hundred day moving average price of $90.87. The stock has a market capitalization of $7.74 billion, a PE ratio of -20.01 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period in the previous year, the business posted ($1.28) EPS. Sell-side analysts expect that Nuvalent, Inc. will post -3.86 earnings per share for the current year.

Institutional Trading of Nuvalent

Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the period. US Bancorp DE increased its position in shares of Nuvalent by 10.0% during the third quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after buying an additional 188 shares during the period. Kennedy Capital Management LLC increased its holdings in Nuvalent by 3.7% during the 2nd quarter. Kennedy Capital Management LLC now owns 5,504 shares of the company’s stock worth $420,000 after acquiring an additional 196 shares during the period. Arizona State Retirement System lifted its stake in Nuvalent by 1.9% in the 3rd quarter. Arizona State Retirement System now owns 11,778 shares of the company’s stock worth $1,019,000 after purchasing an additional 220 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Nuvalent by 7.7% in the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock worth $285,000 after purchasing an additional 234 shares during the period. Institutional investors own 97.26% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on NUVL shares. JPMorgan Chase & Co. decreased their target price on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Cantor Fitzgerald initiated coverage on Nuvalent in a report on Wednesday, October 15th. They set an “overweight” rating and a $135.00 price objective for the company. HC Wainwright upped their target price on Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. The Goldman Sachs Group increased their target price on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Truist Financial set a $140.00 price objective on shares of Nuvalent in a report on Monday, November 24th. Fifteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $138.33.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.